FR2262995A1 - - Google Patents

Info

Publication number
FR2262995A1
FR2262995A1 FR7507065A FR7507065A FR2262995A1 FR 2262995 A1 FR2262995 A1 FR 2262995A1 FR 7507065 A FR7507065 A FR 7507065A FR 7507065 A FR7507065 A FR 7507065A FR 2262995 A1 FR2262995 A1 FR 2262995A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7507065A
Other versions
FR2262995B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2262995A1 publication Critical patent/FR2262995A1/fr
Application granted granted Critical
Publication of FR2262995B1 publication Critical patent/FR2262995B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7507065A 1974-03-08 1975-03-06 Expired FR2262995B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2744274A JPS5726506B2 (fr) 1974-03-08 1974-03-08

Publications (2)

Publication Number Publication Date
FR2262995A1 true FR2262995A1 (fr) 1975-10-03
FR2262995B1 FR2262995B1 (fr) 1978-07-28

Family

ID=12221217

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7507065A Expired FR2262995B1 (fr) 1974-03-08 1975-03-06

Country Status (18)

Country Link
US (1) US3972859A (fr)
JP (1) JPS5726506B2 (fr)
AT (1) AT348693B (fr)
BE (1) BE826430A (fr)
CA (1) CA1072953A (fr)
CH (1) CH615661A5 (fr)
CS (1) CS186284B2 (fr)
DE (1) DE2509783C2 (fr)
DK (1) DK149862C (fr)
ES (1) ES435405A1 (fr)
FI (1) FI60859C (fr)
FR (1) FR2262995B1 (fr)
GB (1) GB1498048A (fr)
HU (1) HU174077B (fr)
NL (1) NL181658C (fr)
NO (1) NO145691C (fr)
SE (1) SE420718B (fr)
ZA (1) ZA751306B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
ZA815447B (en) * 1980-08-29 1982-08-25 Salk Inst For Biological Studi Peptides affecting gonadal function
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
WO1983002272A1 (fr) * 1981-12-28 1983-07-07 Beckman Instruments Inc Peptides synthetiques ayant une activite de liberation d'hormones pituitaires de croissance
JPS58125819U (ja) * 1982-02-19 1983-08-26 名伸電機株式会社 積算電力量計用パツキン
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2050425A1 (fr) 1990-09-03 1992-03-04 Yoshiaki Uda Composition pharmaceutique et son utilisation avec du mucus
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Ltd Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
AU699748B2 (en) * 1994-05-10 1998-12-10 Hybritech Incorporated Recombinant HK2 polypeptide
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
WO1996012697A2 (fr) 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Composes capables de moduler l'activite du recepteur de calcium
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
CA2192782C (fr) 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
DE69739388D1 (de) 1996-05-01 2009-06-10 Nps Pharma Inc Inorganische am Ionen-Rezeptor aktive Verbindungen
EP0813887A3 (fr) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. Appareil d'ionophorèse
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
WO1998059073A1 (fr) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Procede de detection du cancer du sein
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
AU783087B2 (en) * 1999-08-06 2005-09-22 Genentech Inc. Peptide antagonists of factor VIIA
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2003518075A (ja) * 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1757701A1 (fr) 1999-12-24 2007-02-28 Genentech, Inc. Procédés et compositions pour la prolongation de la demi-vie d'élimination des composés bioactifs
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US7968080B2 (en) * 2003-08-20 2011-06-28 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
KR100935855B1 (ko) * 2003-09-18 2010-01-07 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｋｉｄ3 및 그것과 결합하는 ｋｉｄ3 항체
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
US7572895B2 (en) * 2004-06-07 2009-08-11 Raven Biotechnologies, Inc. Transferrin receptor antibodies
KR20070073886A (ko) * 2004-10-05 2007-07-10 제넨테크, 인크. 독성이 감소된 치료제
EP1846767B1 (fr) * 2005-01-12 2012-06-06 MacroGenics West, Inc. Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci
CA2596115A1 (fr) * 2005-01-31 2006-08-10 Raven Biotechnologies, Inc. Luca2 et anticorps s'y liant
WO2006084078A2 (fr) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Antigene jam-3 et anticorps se liant a celui-ci
CA2596273C (fr) 2005-02-02 2017-11-14 Raven Biotechnologies, Inc. Modulateurs adam-9
CA2597171A1 (fr) * 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Anticorps de recepteur de l'oncostatine m
EP1790656A1 (fr) * 2005-11-25 2007-05-30 Nanokem S.A. Synthèse en phase liquide du leuprolide
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
EP2421551B2 (fr) 2009-04-20 2020-07-15 Allergan, Inc. Hydrogels à base de fibroïnes de soie et leurs utilisations
PL219569B1 (pl) * 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
CA2791658C (fr) 2010-03-04 2019-10-01 Macrogenics, Inc. Anticorps reagissant avec b7-h3, fragments immunologiquement actifs associes et utilisations associees
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
UA117072C2 (uk) 2011-05-21 2018-06-11 Макродженікс, Інк. Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
EP2557163A1 (fr) 2011-08-12 2013-02-13 SymbioGruppe GmbH & Co KG Microcine S formée à bactéries, nouvelle peptide antimicrobienne, effective contre les micro-organismes pathogéniques, par exemple des Escherichia coli entérohémorrhagiques
KR20140068087A (ko) 2011-08-23 2014-06-05 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 펩티드 나노입자 및 이의 용도
EP2751136B1 (fr) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Polypeptides natriurétiques
WO2013103896A1 (fr) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Traitement de maladies cardiovasculaires ou rénales
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN105189561B (zh) 2013-03-14 2021-02-26 宏观基因有限公司 与表达激活受体的免疫效应细胞和由被病毒感染的细胞表达的抗原具有免疫反应性的双特异性分子及其用途
US20160106813A1 (en) 2013-03-29 2016-04-21 Centre National De La Recherche Schientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
MA40069A (fr) 2014-05-29 2021-04-14 Macrogenics Inc Molécules de liaison trispécifiques et leurs procédés d'utilisation
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN114773475B (zh) 2015-07-30 2024-01-12 宏观基因有限公司 Pd-1结合分子和其使用方法
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
WO2021072277A1 (fr) 2019-10-09 2021-04-15 Stcube & Co. Anticorps spécifiques de lag3 glycosylé et leurs procédés d'utilisation
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
AU7859475A (en) 1976-08-26
NL181658B (nl) 1987-05-04
DE2509783A1 (de) 1975-09-11
SE7502520L (fr) 1975-09-09
FI60859B (fi) 1981-12-31
JPS5726506B2 (fr) 1982-06-04
NO145691C (no) 1982-05-12
FR2262995B1 (fr) 1978-07-28
CH615661A5 (fr) 1980-02-15
AT348693B (de) 1979-02-26
DE2509783C2 (de) 1983-02-17
CA1072953A (fr) 1980-03-04
ATA138075A (de) 1978-07-15
SE420718B (sv) 1981-10-26
GB1498048A (en) 1978-01-18
ES435405A1 (es) 1976-12-01
FI60859C (fi) 1982-04-13
NO750763L (fr) 1975-09-09
ZA751306B (en) 1976-01-28
DK92775A (fr) 1975-09-09
JPS50121277A (fr) 1975-09-23
DK149862C (da) 1987-06-15
HU174077B (hu) 1979-10-28
US3972859A (en) 1976-08-03
NL181658C (nl) 1987-10-01
FI750682A (fr) 1975-09-09
CS186284B2 (en) 1978-11-30
BE826430A (fr) 1975-09-08
NL7502564A (nl) 1975-09-10
DK149862B (da) 1986-10-13
NO145691B (no) 1982-02-01

Similar Documents

Publication Publication Date Title
FR2262995B1 (fr)
FR2286104B1 (fr)
IN141186B (fr)
JPS50105090A (fr)
FR2289392B1 (fr)
FI753317A (fr)
FR2272715A1 (fr)
JPS50114366A (fr)
FR2265197A1 (fr)
JPS50118386A (fr)
JPS50129141A (fr)
JPS50103773A (fr)
JPS50100655U (fr)
JPS50117847A (fr)
JPS50131098U (fr)
JPS50132366A (fr)
JPS50136978A (fr)
DD114875A1 (fr)
CH572441A5 (fr)
BG20843A1 (fr)
CH598034A5 (fr)
CH589187A5 (fr)
CH574158A5 (fr)
CH573993A5 (fr)
CH573816A5 (fr)